All Stories

Pliant discontinues late-stage lung disease trial for l...

Pliant Therapeutics has discontinued a phase 2b/3 trial after recording at least...

Fierce Biotech Layoff Tracker 2025: BMS axes 223 jobs; ...

As always, if you know of layoffs occurring at a biotech, please reach out to th...

Boston Scientific snags renal denervation developer Son...

The acquisition sets up the company to potentially compete against Medtronic and...

Sanofi bounces midstage ILT2 asset back to Biond Biolog...

The company is handing back the tumor candidate it snapped up in 2021 after init...

Neumora halts trial of depression drug, rethinks 2 othe...

Neumora halted one trial of its depression drug navacaprant and paused another p...

Fierce Biotech Fundraising Tracker '25: Callio launches...

The Fierce Biotech Fundraising Tracker records venture capital rounds of $50 mil...

Lexicon feels the pain as midphase non-opioid data unde...

Lexicon Pharmaceuticals is yet again defending a mixed set of data on its non-op...

Frazier arms Callio with $187M series A to fly Hummingb...

Frazier Life Sciences has launched Callio Therapeutics with $187 million in seri...

Takeda's $300M bet on Protagonist's blood cancer drug p...

Takeda’s $300 million bet on Protagonist Therapeutics’ hematology asset a year a...

Novo bets up to $354M per target on Gensaic’s tissue-se...

Novo Nordisk has forged a deal with Gensaic, agreeing to pay up to $354 million ...

AbbVie pays Gubra $350M to make late play for obesity s...

AbbVie is paying $350 million to join the obesity race. The outlay, plus up to $...

Cash-strapped Vincerx left mulling future after Oqory r...

Oqory’s planned reverse merger with fellow antibody-drug conjugate company Vince...

GSK gears up for depemokimab debut with twin FDA filing...

With Sunday’s Academy Awards ceremony in the rearview mirror, GSK is looking ahe...

Trump HHS reevaluating Biden administration's $590M bir...

The Department of Health and Human Services is reevaluating a $590 million contr...

Vir, awaiting 'functional cure' data for hep B combo, w...

Vir Biotechnology may be pushing ahead with its combination therapy in hepatitis...

ElevateBio gene therapy lowers levels of toxic protein ...

ElevateBio is seeking out partnerships for its lead gene therapy after the const...

ElevateBio gene therapy lowers levels of toxic protein ...

ElevateBio is seeking out partnerships for its lead gene therapy after the const...

Cryoablation developer Adagio Medical lays off staff, r...

The cryoablation devicemaker Adagio Medical has opted to pause the European laun...

Eli Lilly feels Magnet's pull with molecular glue deal ...

The molecular glue wave that first began years ago is still swelling, with Eli L...

Fierce Biotech Layoff Tracker 2025: Eisai restructures ...

As always, if you know of layoffs occurring at a biotech, please reach out to th...

Praxis flouts phase 3 futility finding, forging ahead w...

Praxis Precision Medicines has been blindsided by a recommendation to stop a pha...

BridgeBio's KRAS-focused cancer spinout backs SPAC as p...

For a while, special purpose acquisition companies were biotech’s hot ticket to ...

Research reveals ‘ticking DNA clock’ behind Huntington’...

This week on "The Top Line," we hear from Steven McCarroll, Ph.D., whose researc...

Chutes & Ladders—Private equity firms take over bluebir...

Gene therapy maker bluebird bio’s 15-year flight has landed in the nest of priva...

This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies.